Informing the Population of Their Level of Protection Against COVID-19 in Monaco: a Prospective Study (MonaVacc)
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 10,000
- 试验地点
- 1
- 主要终点
- Covid-19 Neutralizing Antibodies Measurment
研究概览
简要总结
Vaccines against the coronavirus type 2 causing severe acute respiratory syndrome Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have been created in a short period of time due to the rapid spread of the virus. These vaccines use different and sometimes innovative technologies, such as the use of ribonucleic acid (RNA), or a non-replicating viral vector. Efficacy ranging from 70-90% in the first weeks after the second injection of these vaccines has been reported, with side effects whose causality remains to be determined.
详细描述
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participant must live in the Principality of Monaco
- •Deliver a written consent to participate to the study
- •And/Or Have been infected with SARS-CoV-2
- •And/Or Have been, or are about to be, vaccinated against SARS-CoV-2
排除标准
- •None of the above
结局指标
主要结局
Covid-19 Neutralizing Antibodies Measurment
时间窗: 24-month period
Inform any individual who has been infected with or vaccinated against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have about their level of immune protection, through a bi-annual follow-up
次要结局
未报告次要终点